Compare HIND & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIND | CCM |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | China |
| Employees | 18 | N/A |
| Industry | | Medical/Nursing Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 14.9M |
| IPO Year | 2016 | 2009 |
| Metric | HIND | CCM |
|---|---|---|
| Price | $2.07 | $4.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 16.8K | ★ 23.8K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $3.18 |
| 52 Week High | $12.87 | $10.77 |
| Indicator | HIND | CCM |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 73.81 |
| Support Level | $2.02 | $3.64 |
| Resistance Level | $2.43 | $4.99 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 31.11 | 36.89 |
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.